Literature DB >> 24023074

Diabetes mellitus: long-term prognostic value of whole-body MR imaging for the occurrence of cardiac and cerebrovascular events.

Fabian Bamberg1, Klaus G Parhofer, Elena Lochner, Roy P Marcus, Daniel Theisen, Hannes M Findeisen, Udo Hoffmann, Stefan O Schönberg, Christopher L Schlett, Maximilian F Reiser, Sabine Weckbach.   

Abstract

PURPOSE: To study the predictive value of whole-body magnetic resonance (MR) imaging for the occurrence of cardiac and cerebrovascular events in a cohort of patients with diabetes mellitus (DM).
MATERIALS AND METHODS: This HIPAA-compliant study was approved by the institutional review board. Informed consent was obtained from all patients before enrollment into the study. The authors followed up 65 patients with DM (types 1 and 2) who underwent a comprehensive, contrast material-enhanced whole-body MR imaging protocol, including brain, cardiac, and vascular sequences at baseline. Follow-up was performed by phone interview. The primary endpoint was a major adverse cardiac and cerebrovascular event (MACCE), which was defined as composite cardiac-cerebrovascular death, myocardial infarction, cerebrovascular event, or revascularization. MR images were assessed for the presence of systemic atherosclerotic vessel changes, white matter lesions, and myocardial changes. Kaplan-Meier survival and Cox regression analyses were performed to determine associations.
RESULTS: Follow-up was completed in 61 patients (94%; median age, 67.5 years; 30 women [49%]; median follow-up, 70 months); 14 of the 61 patients (23%) experienced MACCE. Although normal whole-body MR imaging excluded MACCE during the follow-up period (0%; 95% confidence interval [CI]: 0%, 17%), any detectable ischemic and/or atherosclerotic changes at whole-body MR imaging (prevalence, 66%) conferred a cumulative event rate of 20% at 3 years and 35% at 6 years. Whole-body MR imaging summary estimate of disease was strongly predictive for MACCE (one increment of vessel score and each territory with atherosclerotic changes: hazard ratio, 13.2 [95% CI: 4.5, 40.1] and 3.9 [95% CI: 2.2, 7.5], respectively), also beyond clinical characteristics as well as individual cardiac or cerebrovascular MR findings.
CONCLUSION: These initial data indicate that disease burden as assessed with whole-body MR imaging confers strong prognostic information in patients with DM. Online supplemental material is available for this article. © RSNA, 2013.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24023074     DOI: 10.1148/radiol.13130371

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  17 in total

1.  Effect of team training on improving MRI study completion rates and no-show rates.

Authors:  Alexander Norbash; Kent Yucel; William Yuh; Gheorghe Doros; Amna Ajam; Elvira Lang; Stephen Pauker; Nina Mayr
Journal:  J Magn Reson Imaging       Date:  2016-04-06       Impact factor: 4.813

Review 2.  Imaging-based characterization of cardiometabolic phenotypes focusing on whole-body MRI--an approach to disease prevention and personalized treatment.

Authors:  Sergios Gatidis; Christopher L Schlett; Mike Notohamiprodjo; Fabian Bamberg
Journal:  Br J Radiol       Date:  2016-01-18       Impact factor: 3.039

3.  [Imaging in syndrome complex diabetes mellitus: Current standards and future perspectives].

Authors:  H Hetterich; A Schafnitzel; F Bamberg
Journal:  Radiologe       Date:  2015-04       Impact factor: 0.635

4.  [Prognostic value of cardiovascular MRI in diabetics].

Authors:  C L Schlett; R C Bertheau; H-U Kauczor; S Weckbach
Journal:  Radiologe       Date:  2015-04       Impact factor: 0.635

5.  Whole-body MRI in patients with Non-bacterial Osteitis: Radiological findings and correlation with clinical data.

Authors:  A P Arnoldi; C L Schlett; H Douis; L L Geyer; A M Voit; F Bleisteiner; A F Jansson; S Weckbach
Journal:  Eur Radiol       Date:  2016-09-23       Impact factor: 5.315

6.  Whole-Body MR Imaging Including Angiography: Predicting Recurrent Events in Diabetics.

Authors:  Robert C Bertheau; Fabian Bamberg; Elena Lochner; Hannes M Findeisen; Klaus G Parhofer; Hans-Ulrich Kauczor; Stefan O Schoenberg; Sabine Weckbach; Christopher L Schlett
Journal:  Eur Radiol       Date:  2015-08-25       Impact factor: 5.315

7.  Prevalence and Distribution of Atherosclerosis in a Low- to Intermediate-Risk Population: Assessment with Whole-Body MR Angiography.

Authors:  Matthew A Lambert; Jonathan R Weir-McCall; Marco Salsano; Stephen J Gandy; Daniel Levin; Ian Cavin; Roberta Littleford; Jennifer A MacFarlane; Shona Z Matthew; Richard S Nicholas; Allan D Struthers; Frank Sullivan; Shelley A Henderson; Richard D White; Jill J F Belch; J Graeme Houston
Journal:  Radiology       Date:  2018-05-01       Impact factor: 29.146

8.  Association of early left ventricular dysfunction with advanced magnetic resonance white matter and gray matter brain measures: The CARDIA study.

Authors:  Anderson C Armstrong; Majon Muller; Bharath Ambale-Venkatesh; Michael Halstead; Satoru Kishi; Nick Bryan; Stephen Sidney; Luís C L Correia; Samuel S Gidding; Lenore J Launer; João A C Lima
Journal:  Echocardiography       Date:  2017-11-08       Impact factor: 1.874

9.  Cohort comparison study of cardiac disease and atherosclerotic burden in type 2 diabetic adults using whole body cardiovascular magnetic resonance imaging.

Authors:  Suzanne L Duce; Jonathan R Weir-McCall; Stephen J Gandy; Shona Z Matthew; Deirdre B Cassidy; Lynne McCormick; Petra Rauchhaus; Helen Looker; Helen M Colhoun; J Graeme Houston
Journal:  Cardiovasc Diabetol       Date:  2015-09-18       Impact factor: 9.951

10.  Common carotid intima media thickness and ankle-brachial pressure index correlate with local but not global atheroma burden: a cross sectional study using whole body magnetic resonance angiography.

Authors:  Jonathan R Weir-McCall; Faisel Khan; Matthew A Lambert; Carly L Adamson; Michael Gardner; Stephen J Gandy; Prasad Guntur Ramkumar; Jill J F Belch; Allan D Struthers; Petra Rauchhaus; Andrew D Morris; J Graeme Houston
Journal:  PLoS One       Date:  2014-06-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.